MARKET

GILD

GILD

Gilead Sciences Inc
NASDAQ
111.87
+2.23
+2.03%
Opening 10:55 07/14 EDT
OPEN
109.77
PREV CLOSE
109.64
HIGH
112.03
LOW
109.66
VOLUME
1.73M
TURNOVER
--
52 WEEK HIGH
118.28
52 WEEK LOW
64.27
MARKET CAP
139.16B
P/E (TTM)
23.66
1D
5D
1M
3M
1Y
5Y
1D
Gilead Presents New Phase 3 Data Showing Twice-Yearly Injectable PrEP Yeztugo Is Effective, Well Tolerated, And Preferred Over Daily Pills Across Diverse Populations, Including Pregnant Women And Adolescents
Benzinga · 11h ago
Gilead Sciences Says Gilead Researchers And Collaborators To Present New Phase 3 PURPOSE Trial Data For HIV Prevention At IAS 2025
Benzinga · 11h ago
GILEAD PRESENTS NEW DATA ON TWICE-YEARLY LENACAPAVIR (YEZTUGO®) FOR HIV PREVENTION AT IAS 2025
Reuters · 11h ago
Gilead price target raised to $114 from $105 at Leerink
TipRanks · 12h ago
Gilead Sciences Secures FDA Approval for Yeztugo as HIV Prevention PrEP and Pursues Accelerated Regulatory Reviews Globally
Reuters · 12h ago
BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Crypto stocks, Kraft Heinz
Reuters · 13h ago
BUZZ-Leerink Partners raises PT on Gilead, citing HIV treatments prospects
Reuters · 14h ago
Weekly Report: what happened at GILD last week (0707-0711)?
Weekly Report · 15h ago
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.

Webull offers Gilead Sciences Inc stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.